Recently, evidence of complement activation in COVID-19, including elevated serum concentrations of C5a and C5b-9, increased leukocyte CD11b expression (which can result from C5aR1 activation), and post-mortem immunochemistry, has been linked to disease severity [8]. Here, C5AR1 is linked to COVID-19.